Korglutide

Korglutide is a synthetic GLP-1 peptide composed of 7 amino acids developed by Caregen as a next-generation nutraceutical solution for weight loss and metabolic health. Designed for once-daily oral administration, Korglutide offers a convenient alternative to injectable GLP-1 receptor agonists such as semaglutide and liraglutide.

• In a randomized, double-blind, placebo-controlled Phase III study in obese individuals (BMI ≥ 30) and obese individuals with type 2 diabetes (BMI ≥ 27), Korglutide demonstrated significant improvements across key metabolic parameters. Body weight decreased by -10.78% (-9.3 kg), BMI by -10.83%, HbA1c by -0.9%, WHR by -5.2%, and body fat mass by -7.1% (-6.65 kg) while skeletal muscle mass reduction remained limited to -2.9% (-0.27 kg).
• A second Phase III study in non-obese individuals including NWO (Normal Weight Obesity) showed -8.02% (-5.2 kg) reduction in body weight and -8.26% reduction in BMI, with body fat decreased by -9.6% and visceral fat level reduced by -9.21%.

These results indicate that Korglutide supports fat reduction while minimizing muscle loss in both obese and non-obese individuals.